Print version ISSN 1020-4989
Rev Panam Salud Publica vol.19 n.1 Washington Jan. 2006
Fernando A. ProiettiI, *; Anna Bárbara F. Carneiro-ProiettiII
IUniversidade Federal de Minas Gerais, Faculdade de Medicina, Departamento de Medicina Preventiva e Social, Belo Horizonte, Minas Gerais, Brazil
IIFundação Hemominas, Belo Horizonte, Minas Gerais, Brazil
It has been 25 years since the discovery of the first human retrovirus, human T-cell leukemia virus type 1 (HTLV-1) (1). Soon after HTLV-1 was discovered, a second human retrovirus, HTLV-2, was described (2). In 2005, two new human retroviruses, HTLV-3 and HTLV-4, were reported in central Africa (3, 4). HTLV-1 was the first retrovirus linked to human disease (5). It has been convincingly associated with adult T-cell leukemia/lymphoma (ATL), HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), uveitis, and infective dermatitis (6-9).
The viruses, especially HTLV-1, have a worldwide distribution (10). Although the exact number of individuals who are seropositive for HTLV-1 or HTLV-2 is not known, it is estimated that about 15 to 20 millions persons (mostly HTLV-1-seropositive) live with these infections worldwide (10). The areas of the world with the highest prevalence rates for HTLV-1 include southwestern Japan, several countries in sub-Saharan Africa, Central America, and localized areas of Iran and of Melanesia. Higher prevalence rates are also found in several countries in the Caribbean, and somewhat lower seroprevalence rates are found in several nations in South America (10). Known modes of HTLV-1 transmission include mother to child, predominantly through breast-feeding; sexual intercourse; and parenteral transmission by transfusion of infected cellular blood products or sharing of needles and syringes.
In the Caribbean, Jamaica and Trinidad and Tobago have relatively high (up to 6%) HTLV-1 or HTLV-1/2 seroprevalence rates in the general population or in specific groups of individuals such as pregnant women and prospective blood donors (11, 12). Although no studies with representative samples of the general population have been conducted so far in South America, lower seroprevalence rates are found in several countries, including Brazil and Colombia (10). Data from Argentina, Brazil, Colombia, and Peru are for the most part restricted to specific groups such as blood donors (up to 2% of seropositivity for HTLV-1/2), pregnant women, Amerindian tribes, and intravenous drug users. Several studies have reported that indicators of lower socioeconomic status, such as having fewer years of schooling, are associated with HTLV-1/2 infection in both endemic and nonendemic areas (13, 14). This suggests that social and environmental factors associated with poverty may influence HTLV transmission. Similarly, HTLV-1-endemic countries (except Japan) have low per capita incomes and fewer resources to deal with a higher burden of HTLV-1/2 infection and associated diseases. The impact of HTLV-1-associated diseases on individuals and their communities is often devastating. No preventive vaccine exists, and the prognosis for ATL and HAM/TSP is poor, in terms of both survival and quality of life (15). HAM/TSP is a long-lasting, progressive disease, and the financial costs for the infected individuals, their families, and health systems are immense. Given these realities, public health interventions such as counseling and the education of high-risk individuals and populations are of great importance.
HTLV screening of donated blood has been routinely implemented in Brazil, Canada, the United States, and other countries in the Americas. Although no specific studies have evaluated this intervention, it has certainly diminished the occurrence of new infections among blood recipients. However, for many other countries in the Americas, this intervention is not systematic and/or permanent, or it is not done at all. The development of adequate, cost-effective strategies for HTLV screening of donated blood should be carefully considered in many countries in the Americas. Also, preventing mother-to-child transmission would probably have a substantial impact on the occurrence of HTLV-associated diseases. As is done for blood donations, prenatal screening for HTLV-1 should be implemented at least for countries, states, cities, or even smaller geographic units with high seroprevalence rates for HTLV-1/2. This should be done in combination with counseling of seropositive mothers regarding transmission through breast-feeding. Since HTLV can be transmitted through sexual contact, there should be an emphasis on condom use, avoiding multiple and unknown sexual partners, and not paying or receiving money for sex. Finally, utilizing counseling and education to encourage intravenous drug users to use harm reduction practices may be effective in preventing HTLV-1/2 infection in this population group.
1. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A. 1980;77(12):74159.
2. Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science. 1982;218:5713.
3. Wolfe ND, Heneine W, Carr JK, Garcia AD, Shanmugam V, Tamoufe U, et al. Emergence of unique primate T-lymphotropic viruses among central African bushmeat hunters. Proc Natl Acad Sci U S A. 2005;102:79949.
4. Calattini S, Chevalier AS, Duprez R, Bassot S, Froment A, Mahieux R, et al. Discovery of a new human T-cell lymphotropic virus (HTLV-3) in Central Africa. Retrovirology. 2005; 2(1):30.
5. Yoshida M, Seiki M, Yamaguchi K, Takatsuki K. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci U S A. 1984;81:25347.
6. Takatsuki K, Uchiyama T, Sagawa K, Yodoi J. Adult T-cell leukemia in Japan. In: Seno S, Takaku F, Irino S, eds. Topics in hematology. Amsterdam: Excerpta Medica; 1977. Pp. 737.
7. Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A, et al. Antibodies to human Tlymphotropic virus type I in patients with tropical spastic paraparesis. Lancet. 1985;2(8452): 40710.
8. Mochizuki M, Watanabe T, Yamaguchi K, Tajima K, Yoshimura K, Nakashima S, et al. Uveitis associated with human T-cell lymphotropic virus type I: seroepidemiologic, clinical and virologic studies. J Infect Dis. 1992;166:9434.
9. LaGrenade L, Hanchard B, Fletcher V, Cranston B, Blattner W. Infective dermatitis in Jamaican children: a marker for HTLV-I infection. Lancet. 1990;336:13456.
10. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene. 2005;24:605868.
11. Hanchard B. Adult T-cell leukemia/lymphoma in Jamaica: 19861995. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13:S20S25.
12. Murphy EL, Figueroa JB, Gibbs WN, Holding-Cobham M, Cranston B, Malley K, et al. Human T-lymphotropic virus type I (HTLV-I) seroprevalence in Jamaica. I. Demographic determinants. Am J Epidemiol. 1991;133:111424.
13. Catalan-Soares BC, Carneiro-Proietti ABF, Proietti FA. HTLV-I/II and blood donors: determinants associated with seropositivity in a low risk population. Rev Saude Publica. 2003;37: 4706.
14. Catalan-Soares B, Carneiro-Proietti ABF, Proietti FA. Heterogeneous geographic distribution of human T-cell lymphotropic viruses I and II (HTLV-I/II): serological screening prevalence rates in blood donors from large urban areas in Brazil. Cad Saude Publica. 2005;21(3): 92631.
15. Ishikawa T. Current status of therapeutic approaches to adult T-cell leukemia. Int J Hematol. 2003;78:30411.
* Send correspondence to: Fernando A. Proietti, Departamento de Medicina Preventiva e Social, Faculdade de Medicina, Universidade Federal de Minas Gerais, Av. Prof. Alfredo Balena, 190, 10° andar, Santa Efigênia, 31130-100 - Belo Horizonte, MG, Brazil; telephone: 5531-32489102; fax: 5531-32489949; e-mail: firstname.lastname@example.org